[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Lebanon\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":699},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,66,0,25,[9,42,72,107,136,165,202,226,247,268,303,333,358,382,412,436,459,479,513,537,561,593,614,643,668],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100583472",false,"NCT06876766","Effect of Pediatric Lung Ultrasound on Antibiotic Prescriptions in Hospitalized Children and Adolescents With Lower Respiratory Tract Infections. A Randomized Controlled Trial.","Effect of Pediatric Lung Ultrasound on Antibiotic Prescriptions in Hospitalized Children and Adolescents With Lower Respiratory Tract Infections.","PLUS-AP","Inclusion Criteria:\n\n* Age between 3 months and 17 years old inclusive\n* Currently admitted to the pediatric Ward or boarding in the Emergency Department within 24 hours of admission order due to lower respiratory tract infections.\n\nExclusion Criteria:\n\n* Sickle cell disease (SCD).\n* On chemotherapy or any other immunosuppressive therapy except systemic corticosteroids use of ≤ 5 days duration.\n* Cystic fibrosis and other chronic lung diseases except asthma\n* Pre-existing and\u002For congenital neurologic, metabolic, and cardiac conditions\n* Hospitalized within the previous month\n* Patients with suspected foreign body aspiration -Received antibiotic therapy within the previous week\n* Patients admitted under PI's care","ALL","3 Months","18 Years",{"count":21,"type":22},176,"ESTIMATED","INTERVENTIONAL",[25],"NA","Title: Effect of Pediatric Lung Ultrasound on Antibiotic Prescriptions in Hospitalized Children and Adolescents with Lower Respiratory Tract Infections (PLUS-AP Trial)\n\nPurpose of the Study:\n\nThis study is being done to find out if a type of imaging called lung ultrasound (LUS) can help doctors decide when to stop antibiotics in children and teens who are in the hospital with lung infections, like pneumonia. Antibiotics are often given to these patients, but sometimes they are used for longer than necessary, which can be harmful. The investigators want to see if using LUS helps doctors make decisions that reduce unnecessary antibiotic use, which can help prevent antibiotic resistance and other complications.\n\nWhat is Lung Ultrasound (LUS)? Lung ultrasound is a safe, non-invasive, and painless test that uses sound waves to look at the lungs. It doesn't involve radiation like chest X-rays. It is already being used to help doctors understand lung conditions, and this study will test if it can also help in deciding when to stop antibiotics.\n\nHow the Study Works:\n\nParticipants: Children and adolescents (ages 3 months-18 years) who are admitted to the hospital with a lung infection.\n\nGroups:\n\nLUS Group: These patients will have a lung ultrasound within 24 hours of enrollment. The results will help guide decisions about when to stop antibiotics.\n\nStandard Care Group: These patients will receive regular hospital care, which may include chest X-rays and other tests to guide their treatment.\n\nWhat Will Be Measured?\n\nPrimary Goal: The study will measure how long children and teens stay on antibiotics. The investigators are testing whether LUS can help shorten this time without affecting their recovery.\n\nSecondary Goals: Investigators will also look at how long patients stay in the hospital, whether they need further treatment or care after leaving.\n\nWhy is This Important? If this study shows that LUS can safely reduce the use of antibiotics, it could change how doctors treat lung infections in children. Reducing unnecessary antibiotic use can help fight antibiotic resistance and protect children from side effects of unnecessary treatments.",[28],"Lower Resp Tract Infection","RECRUITING","2026-06-30",{"date":32,"type":33},"2026-07-02","ACTUAL",{"date":35,"type":33},"2025-04-02",{"date":37,"type":22},"2027-06",{"name":39,"class":40},"American University of Beirut Medical Center","OTHER",1,{"id":43,"slug":4,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":23,"phases":50,"briefSummary":52,"conditions":53,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100367421","NCT04064060","A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials","A Phase 3b, Open-label, Single-arm, Rollover Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials","Inclusion Criteria:\n\nParticipants must meet all the following criteria to be enrolled in this study:\n\n1. Participant is ≥ 18 years at the time of signing the informed consent form (ICF).\n2. Participant is willing and able to adhere to the study visit schedule and other protocol requirements.\n3. Participant has been participating in a luspatercept trial and continues to fulfill all the requirements of the parent protocol and the participant has been either:\n\n   1. Assigned to luspatercept treatment, continues to receive clinical benefit in the opinion of the investigator and should continue to receive luspatercept treatment, OR\n   2. Assigned to placebo arm in the parent protocol (at the time of unblinding or in follow-up) and should cross over to luspatercept treatment, OR\n   3. Assigned to the Follow-up Phase of the parent protocol, previously treated with luspatercept or placebo in the parent protocol who shall continue into LTPTFU phase in the rollover study until the follow-up commitments are met (unless requirements are met as per parent protocol to crossover to luspatercept treatment).\n4. Participant understands and voluntarily signs an informed consent document prior to any study-related assessments or procedures being conducted.\n5. Participant demonstrates compliance, as assessed by the investigator, with the parent study protocol requirements.\n6. Applies to on treatment Participants only- females of childbearing potential (FCBP) defined as a sexually mature woman who:\n\n1\\) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy or amenorrhea due to other medical reasons does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months) must:\n\n1. Have two negative pregnancy tests as verified by the investigator prior to starting study therapy. She must agree to ongoing pregnancy testing during the course of the study, and after end of study therapy. This applies even if the participant practices true abstinence from heterosexual contact.\n2. Agrees to use, and be able to comply with highly effective, contraception without interruption, 35 days prior to starting investigational product (IP), during the study therapy (including dose interruptions), and for 84 days after discontinuation of study therapy.\n\n   7\\. Applies to on treatment participants only- Male participants must:\n\na. Agrees to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 84 days following investigational product discontinuation even if he has undergone a successful vasectomy.\n\nExclusion Criteria:\n\nThe presence of any of the following will exclude a participant from enrollment:\n\n1. Applies to on treatment participants only- Concomitant use of any medications\u002Fprocedures that are prohibited in the parent luspatercept protocol.\n2. Participant has met one or more criteria for study discontinuation as stipulated in the parent luspatercept protocol.\n3. Applies to on treatment participants only- More than 26 days between last luspatercept dose in the parent protocol and first dose into ACE-536-LTFU-001 protocol unless dose delay or dose discontinuation criteria met.\n4. Applies to on treatment participants only- Pregnant or breastfeeding females.\n5. Participant has any significant medical condition, laboratory abnormality, psychiatric illness, or is considered vulnerable by local regulations (eg, imprisoned or institutionalized) that would prevent the subject from participating in the study.\n6. Participant has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he\u002Fshe were to participate in the study.\n7. Participant has any condition that confounds the ability to interpret data from the study.",{"count":49,"type":22},665,[51],"PHASE3","A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following participants:\n\n* Participants receiving luspatercept on a parent protocol at the time of their transition to the rollover study, who tolerate the protocol-prescribed regimen in the parent trial and, in the opinion of the investigator, may derive clinical benefit from continuing treatment with luspatercept\n* Participants in the follow-up phase previously treated with luspatercept or placebo in the parent protocol will continue into long-term post-treatment follow-up in the rollover study until the follow-up commitments are met\n* The study design is divided into the Transition Phase, Treatment Phase and Follow-up Phase. Participants will enter transition phase and depending on their background will enter either the treatment phase or the Long-term Post-treatment Follow-up (LTPTFU) phase\n* Transition Phase is defined as one Enrollment visit\n* Treatment Phase: For participants in luspatercept treatment the dose and schedule of luspatercept in this study will be the same as the last dose and schedule in the parent luspatercept study. This does not apply to participants that are in long-term follow-up from the parent protocol\n* Follow-up Phase includes:\n\n  \\- 42 Day Safety Follow-up Visit\n* During the Safety Follow up, the participants will be followed for 42 days after the last dose of luspatercept, for the assessment of safety-related parameters and adverse event (AE) reporting\n\n  \\- Long-term Post-treatment Follow-up (LTPTFU) Phase\n* Participants will be followed for overall survival every 6 months for at least 5 years from first dose of luspatercept in the parent protocol, or 3 years of post-treatment from last dose, whichever occurs later, or until death, withdrawal of consent, study termination, or until a subject is lost to follow-up. Participants will also be monitored for progression to AML or any malignancies\u002Fpre-malignancies. New anticancer or disease related therapies should be collected at the same time schedule\n\nParticipants transitioning from a parent luspatercept study in post-treatment follow-up (safety or LTPTFU) will continue from the same equivalent point in this rollover study.\n\nThe ACE-536-LTFU-001 rollover study will be terminated, and relevant participants will discontinue from the study when all participants fulfill 5 years on the study, including treatment and follow-up.",[54,55,56],"Myelodysplastic Syndromes (MDS)","Beta-thalassemia","Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis",[58,59,60,55,61],"ACE-536","Luspatercept","MDS","Myeloproliferative neoplasm (MPN)-associated myelofibrosis",{"date":63,"type":33},"2026-07-01",{"date":65,"type":33},"2019-08-12",{"date":67,"type":22},"2028-05-12",{"name":69,"class":70},"Celgene","INDUSTRY",143,{"id":73,"slug":4,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":91,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":41},"100644562","NCT07671482","Effects of Kinesio Taping Versus McConnell Taping on Clinical Outcomes in Patients With Patellofemoral Pain Syndrome.","Effects of Kinesio Taping Versus McConnell Taping on Clinical Outcomes in Patients With Patellofemoral Pain Syndrome. A Randomized Clinical Trial.","PFPS","Inclusion Criteria:\n\n* Anterior or retropatellar pain for a minimum of 3 months during functional activities.\n* 18-50 years of age.\n* Minimum pain of 3\u002F10 on the VAS score.\n* No LL physical therapy in the past 3 months.\n\nExclusion Criteria:\n\n* Meniscal or ligamentous injury\n* Neurological or systemic conditions affecting proprioception, coordination and balance.\n* Spinal referred pain or rheumatoid arthritis.\n* Hip and ankle disorders.","50 Years",{"count":81,"type":22},80,[25],"The primary goal of this randomized clinical trial (RCT) is to evaluate whether Kinesio Taping versus McConnell Taping, when integrated into a standardized hip-knee strengthening and neuromuscular control program, produces significant effects in individuals aged 18-50 with patellofemoral pain syndrome (PFPS).\n\nThe main question it aims to answer is: Does Kinesio Taping compared with McConnell Taping when both combined with a standardized hip-knee exercise program, produce different effects on quadriceps neuromuscular activation (VMO-VL sEMG), pain, functional knee pain, and dynamic knee valgus over a 6 week period intervention?\n\nParticipants will be divided into three groups for comparison: the control group will receive a structured hip-knee physical therapy exercise program without any taping intervention, Kinesio Taping group with a standardized exercise program, and a McConnell Taping group with a standardized exercise program.",[85,86,77,87,88,89,90],"Patello Femoral Pain Syndrome","Anterior Knee Pain Syndrome","Patellofemoral Pain Syndrome","Patellofemoral Disorder","Patellofemoral Pain, PFP","Patellofemoral Pain (PFPS)",[92,93,94,95,96,87,97],"Electromyography","EMG","Kinesio Taping","McConnell Taping","Exercise Therapy","Single-Leg Squat","2026-06-25",{"date":100,"type":33},"2026-06-26",{"date":102,"type":22},"2026-06",{"date":104,"type":22},"2026-10",{"name":106,"class":40},"Cairo University",{"id":108,"slug":4,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":23,"phases":116,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":131,"completionDateStruct":132,"leadSponsor":134,"locationsCount":41},"100643946","NCT07667855","Peri-implant Soft Tissue Augmentation Using Microneedling With i-PRF vs. Connective Tissue Graft","Peri-implant Soft Tissue Augmentation Using Microneedling With i-PRF vs. Connective Tissue Graft: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Systemically healthy adults (Between 18 and 65) with one or more dental implants requiring second-stage surgery in the esthetic zone (Anteriors and Premolars).\n* Thin soft tissue phenotype: mucosal thickness or KTW \\\u003C2 mm buccally.\n* Stable osseointegrated implant, adequate restorative space, and healthy adjacent teeth.\n* Good oral hygiene (PI ≤10%), with peri-implant maintenance.\n* Signed consent + willingness for 1-year follow-up.\n\nExclusion Criteria:\n\n* Heavy smokers (≥10 cig\u002Fday); light smokers only if reduced.\n* Systemic\u002Fhealing issues: uncontrolled diabetes, immunocompromise, bleeding disorders, anticoagulants, steroids.\n* Pregnancy or breastfeeding.\n* Active infection (periodontal or peri-implant).\n* No residual keratinized mucosa on buccal side.\n* Previous graft\u002Faugmentation at the site or recent surgery (\\\u003C6 months).\n* Allergies to anesthetics\u002Fmaterials.\n* Non-compliance with instructions or follow-up.","65 Years",{"count":115,"type":22},24,[25],"This randomized controlled clinical trial aims to evaluate a minimally invasive technique for peri-implant soft tissue augmentation using microneedling combined with injectable platelet-rich fibrin (i-PRF) compared with the current gold-standard connective tissue graft (CTG). Patients with thin peri-implant soft tissue requiring implant second-stage surgery in the esthetic zone will be randomly assigned to receive either CTG harvested from the palate or a series of microneedling and i-PRF treatments. Clinical outcomes including mucosal thickness, keratinized tissue width, peri-implant health parameters, volumetric soft tissue changes, esthetic outcomes, and patient-reported measures of pain and satisfaction will be evaluated during follow-up. The study aims to determine whether microneedling with i-PRF can provide comparable soft tissue augmentation while reducing patient morbidity associated with connective tissue graft harvesting.",[119],"Thin Peri-implant Mucosal Phenotype",[121,122,123,124,125,126,127],"Microneedling","Injectable Platelet-Rich Fibrin","i-PRF","Peri-implant soft tissue augmentation","Implant Esthetics","Mucosal Thickness","Connective Tissue Graft","NOT_YET_RECRUITING","2026-06-19",{"date":98,"type":33},{"date":100,"type":22},{"date":133,"type":22},"2027-03-26",{"name":135,"class":40},"Beirut Arab University",{"id":137,"slug":4,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":142,"targetDuration":144,"studyType":145,"phases":4,"briefSummary":146,"conditions":147,"keywords":150,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":164},"100075056","NCT00231400","Pompe Disease Registry Protocol","Pompe Disease Registry","Inclusion Criteria:\n\nAll patients with a confirmed diagnosis of Pompe disease who have signed the informed consent and authorization form(s) are eligible for inclusion. Confirmed diagnosis is defined as documented GAA enzyme deficiency from blood, skin, or muscle tissue and\u002For documentation of 2 GAA gene mutations.\n\nExclusion Criteria:\n\nThere are no exclusion criteria in this Registry",{"count":143,"type":22},2000,"5 Years","OBSERVATIONAL","The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development\u002Freimbursement, and for other research and non-research related purposes.\n\nThe objectives of the Registry are:\n\n* To enhance understanding of the variability, progression, identification, and natural history of Pompe disease, with the ultimate goal of better guiding and assessing therapeutic intervention.\n* To assist the Pompe medical community with the development of recommendations for monitoring patients, and to provide reports on patient outcomes, to optimize patient care.\n* To characterize the Pompe disease population.\n* To evaluate the long-term effectiveness of alglucosidase alfa.",[148,149],"Glycogen Storage Disease Type II","Pompe Disease",[151,152,149,153,154,155],"Glycogen Storage Disease Type II (GSD-II)","GSD-II","Pompe Disease (late-onset)","Acid Maltase Deficiency Disease","Glycogenosis II",{"date":157,"type":33},"2026-06-23",{"date":159,"type":33},"2004-09-15",{"date":161,"type":22},"2034-01-31",{"name":163,"class":70},"Genzyme, a Sanofi Company",272,{"id":166,"slug":4,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":17,"minAge":171,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":23,"phases":175,"briefSummary":176,"conditions":177,"keywords":180,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":201},"100513799","NCT05970172","A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease","A Phase 3, Open-label, Uncontrolled Study to Evaluate the Activity, Safety, Pharmacokinetics and Pharmacodynamics of Roxadustat for the Treatment of Anemia in Pediatric Participants With Chronic Kidney Disease","Inclusion Criteria:\n\n* Participant has a diagnosis of anemia in CKD Kidney Disease Outcomes Quality Initiative stages 3 or 4 or 5. This can include participants not on dialysis or dialysis dependent (DD) participants (including hemodialysis, peritoneal dialysis and hemodiafiltration participants).\n* Participants not on dialysis must have an estimated glomerular filtration rate (Schwartz formula) of \\\u003C 60 mL\u002Fmin per 1.73 m\\^2.\n* ESA-treated participants should have a screening Hb level, assessed via HemoCue, between 10.0 and 12.0 g\u002FdL; ESA-naïve participants can have a Hb level ≤ 11 g\u002FdL.\n* Participant has a ferritin level \\> 100 ng\u002FmL or a transferrin saturation (TSAT) value \\> 20%.\n* Participant has an alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2 x upper limit of normal (ULN) and total bilirubin (TBL) ≤ 1.5 x ULN at enrollment visit.\n* Participant is treated with an ESA or is ESA-naïve, where ESA status is defined as:\n\n  * ESA-treated: Participant is taking a stable dose of an ESA for at least 4 weeks prior to screening.\n  * ESA-naïve: Participant has no prior ESA exposure OR participant's total prior ESA exposure ≤ 3 weeks within the preceding 4 weeks from screening OR participant was previously treated with and discontinued an ESA ≥ 8 weeks prior to screening.\n* Female participant is not pregnant and at least 1 of the following conditions apply:\n\n  * Not a woman of childbearing potential (WOCBP)\n  * WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 4 weeks after final study intervention administration.\n* Female participant must agree not to breastfeed starting at screening and throughout the study and for 4 weeks post-last roxadustat dose.\n* Female participant must not donate ova starting at first administration of roxadustat and throughout the study period and for 4 weeks post-last roxadustat dose.\n* Male participants with female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period and for 4 weeks post-last roxadustat dose.\n* Male participants must not donate sperm during the treatment period and for 4 weeks post-last roxadustat dose.\n* Male participants with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 4 weeks post-last roxadustat dose.\n* Participant and\u002For participant's parent or legal guardian agrees for the participant not to participate in another interventional study while participating in the present study.\n\nExclusion Criteria:\n\n* Participant has received any investigational therapy within 28 days or 5 half-lives, whichever is longer, prior to screening.\n* Participant has any medical condition, including active, systemic or clinically significant infection which may pose a safety risk to a participant in this study, which may confound the safety or activity assessment or may interfere with study participation making the participant unsuitable for study.\n* Participant has a known or suspected hypersensitivity to roxadustat, related hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHI), or any components of the formulation used.\n* Participant has uncontrolled hypertension (defined as ≥ 95th percentile + 12 mm Hg or ≥ 140\u002F90 mm Hg \\[whichever is lower\\] for participants \\\u003C 13 years of age and ≥ 140\u002F90 mm Hg for participants ≥ 13 years of age measured 3 times at the same visit) in the 2 weeks prior to screening.\n* Participant has a known hematologic disease other than anemia secondary to renal disease,(e.g., history of sickle cell disease, sickle cell anemia, hemoglobin sickle cell disease, or hemoglobin sickle cell beta thalassemia).\n* Participant has untreated hypothyroidism.\n* Participant has severe hyperparathyroidism defined as serum parathyroid hormone (PTH) levels above 1000 pg\u002FmL intact PTH within 4 weeks of screening.\n* Participant has a functioning kidney allograft.\n* Participant has a folate or B12 or carnitine deficiency. Acceptable if treated to normal values within 4 weeks of screening.\n* Participant has a known active malignancy or malignancy within 18 months before the screening visit. Radiation or chemotherapy must be completed at least 12 months before the screening visit.\n* Participant has a scheduled living donor organ transplantation date within 12 weeks of screening. If participant becomes eligible for a kidney transplant during study conduct, the participant should be discontinued.\n* Participant has a whole blood or packed red blood cells (pRBC) transfusion during the 8 weeks prior to screening.\n* Participant has any current condition leading to active significant blood loss in the past 4 weeks.\n* Participant has a diagnosis of hemolytic uremic syndrome within 12 weeks prior to screening.\n\n  * Participant who has a previous diagnosis of atypical hemolytic syndrome must be relapse-free (stable hemoglobin (Hb), normal platelet count, normal serum lactate dehydrogenase, and normal haptoglobin level) for more than 12 weeks prior to screening.\n* Participant has a history of chronic liver disease, including comorbidity with autosomal recessive polycystic kidney disease, cystinosis, and primary hyperoxaluria.\n* Participant had an episode of peritonitis within 30 days of screening.\n* Participant has active inflammation such as glomerulonephritis flare (i.e., lupus nephritis, immunoglobulin A (IgA) nephritis, rapidly progressive glomerulonephritis, membranoproliferative glomerulonephritis, antineutrophil cytoplasmic antibodies vasculitis) requiring pulse corticosteroid treatment or induction treatment with an immunosuppressive agent (i.e., cyclophosphamide, rituximab, or another monoclonal antibody) within 6 weeks of screening visit. Receipt of monoclonal antibody or biologic for maintenance treatment of underlying condition is acceptable.\n* Participant has a known history of human immunodeficiency virus infection.\n* Participant has rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption or is allergic to peanut or soya.","2 Years","17 Years",{"count":174,"type":22},100,[51],"Roxadustat is a licensed medicine to treat anemia in adults with chronic kidney disease (CKD). Anemia is a low level of red blood cells. Current treatment for anemia is to have injections of medicines called erythropoietin stimulating agents (also known as ESAs) to help the bone marrow make more red blood cells. These are often given together with iron. This treatment is also available to children and teenagers with CKD. However, there are some safety concerns with ESAs. Also, as roxadustat is taken orally, this may be another option for treating anemia in children and teenagers with CKD. In this study, children and teenagers with CKD and anemia will take roxadustat for up to 52 weeks to treat their anemia.\n\nThe main aim of the study is to learn how roxadustat affects anemia in children and teenagers with CKD.\n\nThis is an open-label study which means the children and teenagers in the study and the clinic staff know they will be taking roxadustat. In this study, the children and teenagers with CKD who need treatment for anemia can take part. Those currently being treated with an ESA will be switched to roxadustat. Those who have not been treated with an ESA can start on roxadustat straight away. All children and teenagers in the study will take roxadustat 3 times a week for up to 52 weeks (1 year). They will start on a fixed dose of roxadustat for 4 weeks. Blood samples will be taken regularly to check hemoglobin levels. The roxadustat dose may be changed if the blood levels of hemoglobin are too high, too low, or change too quickly. After 4 weeks the dose may be changed, if needed, to keep blood levels of hemoglobin in the blood to just below the normal range.\n\nFirstly, teenagers will take roxadustat. 10 teenagers will take their fixed dose of roxadustat for 4 weeks. They will give blood samples to help the researchers work out the most suitable dose for the rest of the teenagers in the study. When the rest of the teenagers start taking roxadustat at the most suitable dose for teenagers, 10 children will take roxadustat for 4 weeks. These 10 children will give blood samples to help the researchers work out the most suitable dose for the rest of the children in the study. Then, the rest of the children will take roxadustat at the most suitable dose for children.\n\nThere will be many clinic visits during the study. Overnight hospital stays are not expected. There will be 1 visit every 2 weeks for the first 4 weeks of taking roxadustat, then every 4 weeks until the end of treatment. Finally there is 1 visit 4 weeks after treatment has finished.\n\nDuring most visits, the children and teenagers will have their vital signs checked (blood pressure, body temperature and heart rate). Fluid status (how much water is in the body) will also be checked for those who need dialysis. The children and teenagers will also have blood tests and the study doctors will check for any medical problems. The children and teenagers will have a medical examination before their first dose of roxadustat and again at about 24-week (6-month) and 52-week (13-month) visits. They will have an electrocardiogram (ECG) before their first dose of roxadustat and again at the 12-week, 24-week, 36-week, and 52-week visit. They will also have urine tests at the 4-week, 24-week and 52-week visits. At the 52-week visit, the children and teenagers will also have blood tests for hemoglobin and iron levels. The study doctors will also check for any medical problems.",[178,179],"Chronic Kidney Disease","Renal Anemia",[181,182,183,179,184,178,185,186,187,188,189,190,191],"Roxadustat","ASP1517","Pediatric","Chronic renal failure","Renal Insufficiency, Chronic","Anemia","Open-label","Uncontrolled","Safety","Pharmacokinetics","Pharmacodynamics","2026-06-18",{"date":194,"type":33},"2026-06-22",{"date":196,"type":33},"2024-01-16",{"date":198,"type":22},"2027-10-30",{"name":200,"class":70},"Astellas Pharma Global Development, Inc.",47,{"id":203,"slug":4,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":17,"minAge":209,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":23,"phases":212,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":225},"100563138","NCT06612268","A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease","A Global Phase 3, Randomised, Double-blind and Placebo-controlled Study Evaluating the Efficacy and Safety of Etavopivat in Adolescents and Adults With Sickle Cell Disease","Hibiscus 2","Inclusion Criteria:\n\n* Male or female.\n* Age 12 years or above at the time of signing the informed consent.\n* Confirmed diagnosis of sickle cell disease: Documentation of sickle cell disease (SCD) genotype (HbSS, HbSβ0-thalassemia or other sickle cell syndrome variants) based on prior history of laboratory testing or screening test results from central laboratory. Molecular genotyping is not required. SCD genotype may be determined from the results of haemoglobin (Hb) electrophoresis, high-performance liquid chromatography (HPLC) or similar testing. Note that Hb electrophoresis is performed by the central laboratory at screening.\n* Have 1-15 episodes of documented vaso occlusive crises (VOC) within the 12 months prior to screening. Documentation must exist in the participant's medical record prior to randomisation. Events based solely on participant recall without supporting documentation should not be counted towards eligibility.\n* Hb greater than or equal to (≥) 5.0 and less than or equal to (≤) 10.0 g\u002FdL (greater than or equal to (≥) 50 and less than or equal to (≤) 100 g\u002FL) at screening.\n\nExclusion Criteria:\n\n* More than 15 VOCs within the past 12 months prior to screening documented in the participant's medical record. Events based solely on participant recall without supporting documentation should not be counted towards eligibility.\n* Use of voxelotor or similar agent within 28 days prior to starting study treatment or anticipated need for this agent during the study.\n* Use of a selectin antagonist (e.g., crizanlizumab, monoclonal antibody or small molecule) within 28 days or 5 half-lives (whichever is longer) prior to starting study treatment or anticipated need for such agents during the study.\n* Receiving regularly scheduled blood (RBC) transfusion therapy (also termed chronic, prophylactic, or preventive transfusion) or greater than or equal to 6 transfusion events in the previous 12 months (i.e., an average of 1 transfusion event every 60 days).\n* Participants who have received an RBC transfusion for any reason within 60 days of the screening period or 60 days of the randomisation day are only eligible if HbA (adult haemoglobin) less than 10% by Hb electrophoresis is documented prior to starting study treatment.\n* Receiving or use of concomitant medications that are strong inducers of CYP3A4 (cytochrome p450 3a4) within 2 weeks of starting study treatment or anticipated need for such agents during the study.\n* Use of erythropoietin or other haematopoietic growth factor treatment within 28 days of starting study treatment or anticipated need for such agents during the study.\n* Receipt of prior cellular-based therapy (e.g., haematopoietic cell transplant, gene modification therapy).\n* Hepatic dysfunction characterized by:\n\n  * Alanine aminotransferase (ALT) greater than 4.0 × upper limit of normal (ULN) or\n  * Direct bilirubin greater than 3.0 × ULN.\n* Participants who are not taking or are unable to take antimalarial prophylaxis at the time of consent and during the study if they live in areas of endemic malaria where prophylaxis is recommended.\n* Severe renal dysfunction (estimated glomerular filtration rate \\[eGFR\\] at screening, calculated by the central laboratory greater than 30 mL\u002Fmin\u002F1.73 m\\^ 2) or on chronic dialysis.\n* Travelled distance on standardized 6MWT below 100m at screening.","12 Years",{"count":211,"type":22},408,[51],"This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo. Which treatment the participants will get is decided by chance. Etavopivat is a new medicine and is currently being tested in other studies in addition to this one. The study will last for about 2 years.",[215],"Sickle Cell Disease","2026-06-16",{"date":218,"type":33},"2026-06-17",{"date":220,"type":33},"2025-02-17",{"date":222,"type":22},"2029-03-12",{"name":224,"class":70},"Novo Nordisk A\u002FS",174,{"id":227,"slug":4,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":23,"phases":234,"briefSummary":235,"conditions":236,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":41},"100487538","NCT05628389","Phone Enabled Implementation of Cessation Support","PHOENICS","Inclusion Criteria:\n\n* Age 18+\n* A current daily cigarette smoker and\u002For a regular waterpipe smoker (smokes at least 1-2 times\u002Fweek).\n* Not pregnant\n* Reachable by phone\n* Interested in quitting\n* Lives in Greater Beirut Area\n\nExclusion Criteria:\n\n* Patients who use other tobacco products including vape exclusively.\n* Any patient below 18 years old.\n* Cigarette smokers who do not smoke on daily basis.\n* Waterpipe smokers who smoke less than once\u002Fweekly",{"count":233,"type":22},1500,[25],"The tobacco use burden in Lebanon is exceptionally high: 35% of adults are current cigarette smokers and 39% are current waterpipe smokers. Although the World Health Organization endorses evidence-based interventions for population-level tobacco dependence treatment, recommended treatments are not integrated as a routine part of primary care in Lebanon, as is the case in other low-resource settings. The objective of this proposal is to evaluate the comparative effectiveness of promising multi-component interventions for implementing evidence-based cessation treatment in Lebanon's national system of primary health care centers.",[237],"Smoking Cessation","2026-06-10",{"date":240,"type":33},"2026-06-12",{"date":242,"type":33},"2024-03-06",{"date":244,"type":22},"2027-08-31",{"name":246,"class":40},"University of Florida",{"id":248,"slug":4,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":252,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":17,"minAge":171,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":23,"phases":256,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":267},"100562904","NCT06609226","A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia","An Open-label, Multi-centre, Rollover Study to Characterise Long-term Safety and Efficacy of Etavopivat in Adults, Adolescents and Children Who Have Sickle Cell Disease or Thalassaemia and Have Completed a Treatment Period in an Etavopivat Study","FLORAL","Inclusion Criteria:\n\n* Participant must have ongoing participation in an etavopivat parent study for treatment of sickle cell disease (SCD) or thalassaemia and have completed at least a treatment period of the parent study.\n* Participant must have derived clinical benefit from treatment with etavopivat, as determined by the investigator.\n* Any participant with dose reduction or temporary discontinuation will need to be successfully rechallenged to the full dose of etavopivat before transferring.\n* Participants on hydroxyurea (HU), crizanlizumab or l-glutamine oral powder (Endari®) treatment at the time of consent may be eligible if they have been on a stable dose in the parent study as defined at the investigator's discretion. Necessary adjustments related to weight or age are accepted. Participants with temporary dose reductions or pauses due to medical reasons may still be considered to have a stable dose, as determined by the investigator, who will assess the impact of these adjustments based on clinical context and the participant's overall health status.\n\nExclusion Criteria:\n\n* Any disorder, except for conditions associated with SCD or thalassaemia, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.\n* Participant withdrew or had permanent treatment discontinuation from an etavopivat clinical study.\n* Participants on permanent dose reduction (greater than \\[\\>\\] 28 days or more) or ongoing temporary treatment discontinuation.\n* Use of any of the following within the timeframes prior to the transfer visit as stated:\n* Use of haemoglobin S (HbS) polymerisation inhibitors within participation of the parent study or anticipated need for this agent during this study.\n* Use of an experimental selectin antagonist (e.g., monoclonal antibody or small molecule) within the parent study or anticipated need for such agents during this study.\n* Use of erythropoietin or other haematopoietic growth factor treatment for more than 4 consecutive weeks during the parent study or anticipated need of such agents for a maintenance treatment during this study.\n* Receiving or use of concomitant medications that are strong inducers of cytochrome P450 (CYP) 3A4 within 2 weeks of the transfer visit or anticipated need for such agents during the study.\n* Current participation in a study that is not a designated parent study, or planned participation in any other clinical study, for the duration of FLORAL.",{"count":255,"type":22},480,[51],"Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking into how safe treatment with etavopivat is and how well it works over a long period of time. The study will last for up to 264 weeks, but it will end earlier if etavopivat is approved in the participant's country.",[215,259],"Thalassemia","2026-06-08",{"date":238,"type":33},{"date":263,"type":33},"2025-01-10",{"date":265,"type":22},"2030-12-30",{"name":224,"class":70},105,{"id":269,"slug":4,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":11,"sex":17,"minAge":274,"maxAge":275,"enrollmentInfo":276,"targetDuration":4,"studyType":23,"phases":278,"briefSummary":280,"conditions":281,"keywords":284,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":295,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":302},"100429857","NCT04877522","Asciminib Roll-over Study","An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment","Key Inclusion Criteria:\n\n1. Participant with PH+ CML or PH+ ALL currently receiving treatment with asciminib (single agent or in combination with imatinib, nilotinib or dasatinib), imatinib, nilotinib or bosutinib alone within a Novartis-sponsored study and, in the opinion of the Investigator, would benefit from continued treatment.\n2. Participant has demonstrated compliance on the parent study protocol and is willing and able to comply with scheduled visits, treatment plans and any other study procedures.\n\nKey Exclusion Criteria:\n\n1. Participant has been discontinued from parent study treatment.\n2. Participant currently has unresolved toxicities reported as possibly related to study treatment in the parent study.\n3. Participant's ongoing treatment is currently approved and reimbursed at country level.\n4. Pregnant or nursing (lactating) women.\n5. Women of child-bearing potential, unless they are using highly effective methods of contraception and willing to continue while taking study treatment.\n6. Sexually active males receiving imatinib, nilotinib, bosutinib or dasatinib unwilling to follow the relevant contraception requirements in the local prescribing information.\n7. Applicable for participants on bosutinib treatment at the end of the CABL001A2301 and on other TKIs for CABL001A2202 study that switch to asciminib treatment:\n\n   * Asymptomatic (grade 2) pancreatitis if not resolved within 28 days\n   * QTcF\\>480msec or inability to determine QTc interval\n   * any grade 3 or 4 toxicity not resolved to grade 2 or lower within 28 days before starting asciminib treatment\n\nOther protocol-defined Inclusion\u002FExclusion criteria may apply.","7 Years","100 Years",{"count":277,"type":22},347,[279],"PHASE4","This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment",[282,283],"Chronic Myelogenous Leukemia","Leukemia, Myelogenous, Chronic, BCR-ABL Positive",[282,285,17,286,287,288,289,290,291,292,293,294],"CML","CML-AP","CML-BP","CML-CP","myeloproliferative neoplasm","chronic phase","accelerated phase","blast phase","ABL001","asciminib",{"date":238,"type":33},{"date":297,"type":33},"2022-08-30",{"date":299,"type":22},"2030-08-30",{"name":301,"class":70},"Novartis Pharmaceuticals",85,{"id":304,"slug":4,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":11,"sex":17,"minAge":309,"maxAge":275,"enrollmentInfo":310,"targetDuration":4,"studyType":23,"phases":312,"briefSummary":313,"conditions":314,"keywords":315,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":332},"100412996","NCT04657822","Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study","An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study","Inclusion Criteria:\n\n1. Written informed consent\u002Fassent, according to local guidelines, signed by the adult patients. In the population under 18 years, it will be signed by the patient and\u002For by the parents or legal guardian prior to enrolling in the rollover study and receiving study medication\n2. SCD patient currently enrolled in a Novartis-sponsored study receiving crizanlizumab and has fulfilled all the requirements in the parent study. Patient is currently benefiting from the treatment with crizanlizumab as determined by the investigator and has completed the treatment schedule as planned in the parent study\n3. Patient has demonstrated compliance to the planned visit schedule in the parent study, and in the opinion of the investigator has shown willingness and ability to comply with future visit schedules\n\nExclusion Criteria:\n\n1. Patient had permanently discontinued from crizanlizumab study treatment in the parent study before the parent study completion\n2. Ongoing\u002Funresolved treatment-related Grade 3 or higher AEs, and\u002For any ongoing AE requiring dose interruption. Patients meeting all other eligibility criteria may be enrolled once toxicities have resolved unless those toxicities were grade 4\n3. Concurrent participation in any other investigational clinical trial other than the parent study or plan to participate in any other investigational clinical trial\n4. Pregnant or nursing women\n5. Women of childbearing potential who are unwilling to be on highly effective contraceptives during dosing and until 15 weeks after stopping treatment with crizanlizumab\n6. SCD patients who do not meet parent study protocol criteria to continue with crizanlizumab","6 Months",{"count":311,"type":22},130,[279],"This is a multi-center multi-national rollover study to allow continued access to crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab treatment in a Novartis-sponsored study (parent study) and are benefiting from the treatment as judged by the investigator.",[215],[316,317,318,319,320,321,322,323,324],"SCD","Vaso-occlusive Crisis","crizanlizumab","SEG101","Sickle cell disease","Sickle cell disorder","VOC","P-selectin","Sickle cell anemia","2026-06-04",{"date":260,"type":33},{"date":328,"type":33},"2021-06-10",{"date":330,"type":22},"2031-06-10",{"name":301,"class":70},31,{"id":334,"slug":4,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":4,"eligibilityCriteria":338,"healthyVolunteers":339,"sex":17,"minAge":19,"maxAge":340,"enrollmentInfo":341,"targetDuration":4,"studyType":23,"phases":343,"briefSummary":344,"conditions":345,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":41},"100636109","NCT07561411","Erector Spinae Block Versus Paravertebral Block on Chronic Pain After Mastectomy","The Effect of Erector Spinae Block Versus Paravertebral Block on the Incidence of Chronic Pain After Mastectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult patients between 18 and 80 years old.\n* Scheduled to total mastectomy with or without axillary dissection\n* Willing to receive regional anesthesia in addition to GA\n* ASA classification 1-3\n\nExclusion Criteria:\n\n* Previous thoracic surgery with an incision of \\>2 cm\n* Patient's refusal\n* Allergy to local anesthetics\n* Pregnant women\n* Any contraindications to thoracic PVB, including intrathoracic infection, infection at the puncture site, cancer invasion of the puncture site, severe spinal deformity, history of spinal surgery, and severe coagulopathy; anticoagulants intake.\n* American Society of Anesthesiologists (ASA) classification of 4 or higher,\n* History of chronic pain or untreated clinical severe depression",true,"80 Years",{"count":342,"type":22},132,[25],"The goal of this clinical trial is to learn if the erector spinae block can reduce the incidence of chronic pain compared to the paravertebral block in adult patients undergoing total mastectomy. The study includes patients aged 18 to 80 years scheduled for mastectomy, with or without axillary dissection. The main questions it aims to answer are:\n\n* Does erector spinae block reduce the incidence of chronic pain at 3 months after mastectomy compared to paravertebral block?\n* Does erector spinae block affect postoperative outcomes such as opioid consumption at 48 hours, pain scores (in PACU, 24 and 48 hours), block performance time, and the incidence of complications, anxiety or depression, and pain intensity at 3 months?\n\nResearchers will compare patients receiving erector spinae block to those receiving paravertebral block to determine if erector spinae block provides equivalent or improved outcomes in terms of chronic pain and perioperative measures.\n\nParticipants will:\n\n* Be randomly assigned to receive either erector spinae block or paravertebral block prior to surgery\n* Undergo total mastectomy (with or without axillary dissection)\n* Have their pain assessed in the PACU and at 24 and 48 hours postoperatively\n* Have opioid consumption measured during the first 48 hours after surgery\n* Be followed up at 3 months to assess chronic pain, pain intensity, and psychological outcomes (anxiety or depression)",[346,347,348,349],"Mastectomy; Lymphedema","Chronic Pain","Regional Anesthesia Morbidity","Opioid Use","2026-06-01",{"date":352,"type":33},"2026-06-02",{"date":354,"type":33},"2026-05-19",{"date":356,"type":22},"2028-05-01",{"name":39,"class":40},{"id":359,"slug":4,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":364,"enrollmentInfo":365,"targetDuration":4,"studyType":145,"phases":4,"briefSummary":366,"conditions":367,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":41},"100563769","NCT06620471","Assessing the Enhanced Precision: The Value of Impedance in Ultrasound-Guided Nerve Blocks (Axillary, Interscalene, Popliteal Sciatic), an Exploratory Prospective Observational Study","Assessing the Enhanced Precision: The Value of Impedance in Ultrasound-Guided Nerve Blocks, an Exploratory Prospective Observational Study","Inclusion Criteria:\n\n* Individuals aged 18 years to 90 years old\n* No infection at the injection site\n* Patient signed the study consent form\n* No contraindications for nerve block\n* No allergies to any of the drugs used\n* Patient able to communicate effectively\n\nExclusion Criteria:\n\n* Patients not meeting the inclusion criteria\n* Patients with bleeding disorders or undergoing anticoagulation therapy\n* Pregnant patients\n* Patients with mental incapacity\n* Any medical conditions posing severe risks during the procedure","90 Years",{"count":174,"type":22},"Impedance can have an impact on nerve block during loco-regional anesthesia, particularly when using techniques such as nerve stimulation or ultrasound guidance to locate and block specific nerves. Impedance refers to the resistance to electrical current flow within tissue, and it can affect the ability to stimulate nerves or visualize them using ultrasound. The aim of this research is to assess the impedance across different tissue type during an axillary peripheral nerve block (skin, fat, fascia, muscle, nerve proximity). The results of this study would help clinicians performing nerve block to enhance the precision of needle placement, thus increase the success rate of nerve block and reduce adverse events such as intraneural or intravascular injections.",[368,369,370,371,372],"Impedance","Axillary Nerve Block","Ultrasound-Guided Nerve Blocks","Interscalene Nerve Block","Popliteal Sciatic Nerve Block","2026-05-18",{"date":375,"type":33},"2026-05-20",{"date":377,"type":33},"2024-06-10",{"date":379,"type":22},"2026-12",{"name":381,"class":40},"Lebanese American University",{"id":383,"slug":4,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":387,"eligibilityCriteria":388,"healthyVolunteers":11,"sex":17,"minAge":209,"maxAge":275,"enrollmentInfo":389,"targetDuration":4,"studyType":23,"phases":391,"briefSummary":392,"conditions":393,"keywords":395,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":411},"100491688","NCT05682378","Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies","An Open-label, Single Arm, Multicenter Extension Study to Evaluate Long-term Safety and Tolerability of Inclisiran in Participants With Heterozygous or Homozygous Familial Hypercholesterolemia Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20 or ORION-19 Studies (VICTORION-PEDS-OLE)","V-PEDS-OLE","Key inclusion:\n\n* Male and female participants with a diagnosis of HeFH or HoFH who completed the ORION-16, ORION-13, ORION-20 or ORION-19 studies\n* Per investigator's clinical judgment, participant derived benefit from treatment with inclisiran in the ORION-16, ORION-13, ORION-20 or ORION-19 studies\n\nKey exclusion:\n\n* Participants who in the feeder ORION-16, ORION-13, ORION-20, or ORION-19 studies either screen failed or permanently discontinued from the treatment\u002Fstudy for any reason or had serious safety or tolerability issues related to inclisiran treatment\n* Any uncontrolled or serious disease, or any medical, physical, or surgical condition, that may either interfere with participation in the clinical study or interpretation of clinical study results, and\u002For put the participant at significant risk",{"count":390,"type":22},195,[51],"The purpose of this open-label, single arm, multicenter extension study is to evaluate the long-term safety and tolerability of inclisiran in participants with HeFH or HoFH who have completed the ORION-16 (CKJX839C12301), ORION-13 (CKJX839C12302), ORION-20 (CKJX839C12303) or ORION-19 (CKJX839C12304) studies.",[394],"Heterozygous or Homozygous Familial Hypercholesterolemia",[396,397,398,399,400,401,402],"KJX839","heterozygous familial hypercholesterolemia","homozygous familial hypercholesterolemia","familial hypercholesterolemia","FH","inclisiran","pediatric","2026-05-13",{"date":405,"type":33},"2026-05-15",{"date":407,"type":33},"2023-02-10",{"date":409,"type":22},"2032-03-28",{"name":301,"class":70},52,{"id":413,"slug":4,"hasResults":11,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":23,"phases":420,"briefSummary":421,"conditions":422,"keywords":424,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":41},"100601477","NCT07111000","Testing the Epley Maneuver for Treating Dizziness in the Emergency Department","Evaluating the Efficacy of Epley Maneuver in the Treatment of Benign Paroxysmal Positional Vertigo in the Emergency Department: A Randomized Controlled Trial.","Inclusion Criteria\n\n* Age: above 18 years old\n* Patients presenting to the ED with symptoms of BPPV (single or recurrent episodes of vertigo lasting up to 2 minutes) and a positive DHT (episode of vertigo associated with torsional upbeating nystagmus) indicating a posterior semicircular canal BPPV.\n* Patients who are able to understand and provide a signed informed consent to participate in the study Exclusion Criteria\n* Severe cervical diseases (e.g., soft tissue disorders, cervical spondylosis, prolapsed intervertebral disks and severe rheumatoid arthritis with cervical instability …)\n* Unstable cardiovascular diseases (e.g., hemodynamically unstable, decompensated heart failure, acute myocardial infarction, decompensated valvular diseases, severe arrhythmias …)\n* Suspected vertebrobasilar diseases (e.g., cerebellar signs, vision changes, numbness or tingling in the extremities, slurred speech, changes in mental status, confusion …)\n* History of high-grade carotid stenosis\n* Recent (\\\u003C24 hours) intake of aminoglycosides, chemotherapeutic agents, cyclophosphamide, loop diuretics, or quinines\n* Patients with peripheral causes of vertigo other than BPPV (such as Meniere's disease or vestibular neuritis)\n* Patients with central causes of vertigo (vestibular migraine, Arnold Chiari malformation, history of CNS tumor(s), multiple sclerosis)\n* Patients with focal deficits on neurological exam\n* Patients with an episode of vertigo lasting more than 2 minutes\n* Patients with a negative DHT\n* Patients with pure horizontal or vertical nystagmus\n* Patients with lateral and anterior semicircular canals BPPV\n* Participants refusing to undergo Epley maneuver\n* Pregnancy beyond the 24th week of gestation",{"count":419,"type":22},118,[25],"The goal of this randomized controlled trial is to evaluate the efficacy of the Epley maneuver versus a sham maneuver in treating patients presenting to the emergency department (ED) with BPPV. The main questions that the study aims to answer are:\n\n* What is the mean difference in Dizziness Handicap Inventory (DHI) scores between patients receiving the Epley maneuver and those receiving the sham maneuver 3 days after enrollment?\n* What is the immediate response (using a 0-10-point Likert scale) of patients in each arm of the study?\n* What is the proportion of patients who, despite agreeing to participate, were unable to complete the full Epley maneuver due to symptom severity?\n\nResearchers will compare the Epley maneuver arm to the sham maneuver arm to see if the Epley maneuver is more effective in reducing BPPV symptoms.\n\nParticipants will:\n\n* Undergo either the Epley maneuver or a sham maneuver.\n* Complete the Dizziness Handicap Inventory (DHI) questionnaire at baseline and 3 days post-discharge.\n* Patients with insufficient improvement in the sham maneuver group will receive a rescue Epley maneuver.\n* Have their vertigo severity assessed using a 0-10 point Likert scale at baseline, immediately and post-maneuver.",[423],"Benign Paroxysmal Positional Vertigo (BPPV)",[425,426,427],"Epley","vertigo","bening paroxysmal positional vertigo","2026-05-06",{"date":430,"type":33},"2026-05-11",{"date":432,"type":33},"2024-08-01",{"date":434,"type":22},"2026-08-22",{"name":39,"class":40},{"id":437,"slug":4,"hasResults":11,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":441,"eligibilityCriteria":442,"healthyVolunteers":11,"sex":17,"minAge":309,"maxAge":19,"enrollmentInfo":443,"targetDuration":4,"studyType":23,"phases":445,"briefSummary":447,"conditions":448,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":458},"100531354","NCT06198712","A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease","A Single Arm, Open Label, Phase 1\u002F2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease","HIBISCUS KIDS","Inclusion Criteria:\n\n* Type of Participant and Disease Characteristics\n\n  1. Patient's parent, legal guardian, or legal representative has provided documented informed consent and patients have provided age-appropriate assent\n  2. Age greater than or equal to (≥) 6 months and lesser than (\\\u003C) 18 years of age at time of enrollment, according to the enrolling cohort:\n\n     * Cohort 1: age 12 to \\\u003C 18 years (adolescents)\n     * Cohort 2: age 6 to \\\u003C 12 years\n     * Cohort 3: age 2 to \\\u003C 6 years\n     * Cohort 4: age 6 months to \\\u003C 2 years\n  3. Patient has confirmed diagnosis of SCD\n\n     • Documentation of SCD genotype (HbSS, HbSβ0-thalassemia or other sickle cell syndrome variants) based on prior history of laboratory testing. Molecular genotyping is not required. SCD genotype may be determined from the results of Hb electrophoresis, high-performance liquid chromatography (HPLC), or similar testing. Note that Hb electrophoresis is performed by the local laboratory at Screening.\n  4. Hemoglobin ≥ 5.5 and lesser than or equal to (≤) 10.5 grams per deciliter (g\u002FdL)\n  5. Pediatric patients with severe SCD, as defined by at least 1 of the following:\n\n     * 2-15 episodes of documented VOC within the 12 months prior to screening. Documentation must exist in the patient's medical record prior to screening. Events based solely on patient recall without supporting documentation should not be counted towards eligibility.\n     * Hospitalization for any SCD-related complication in the last 12 months prior to starting study treatment\n     * Proteinuria, defined as an albumin:creatinine ratio (ACR) \\> 100 mg\u002Fg on 2 measures (separated by ≥ 1 month) as an indicator of early renal disease\n     * History of a conditional TCD in the last 12 months prior to starting study treatment, but not currently being treated with chronic transfusion therapy (applicable to participants \\> 2 years of age). Conditional TCD is defined as a TAMMV of 170-199 cm\u002Fs by TCD or 155-184 cm\u002Fs by imaging TCD (TCDi).\n  6. For participants taking hydroxyurea (HU), the dose of HU (mg\u002Fkg) must be stable (no more than a 20% change in dosing) for at least 90 days prior to start of study treatment with no anticipated need for dose adjustments during the study, in the opinion of the Investigator\n  7. Patients on crizanlizumab or L-glutamine treatment at the time of consent may be eligible if they:\n\n     * Have been on a stable dose for ≥ 12 months at the time of consent (ie, no changes to the dose except for changes to weight or for safety reasons)\n     * For patients on crizanlizumab, have been ≥ 80% compliant with the planned regimen during the 12 months prior to the time of consent\n  8. Female patients of childbearing potential who are using acceptable methods of contraception and agree not to donate ova from study start to 90 days after the last dose of study drug, and male patients who are willing to use acceptable methods of contraception and agree not to donate sperm, from study start to 90 days after the last dose of study drug.\n\nExclusion Criteria:\n\n* Medical Conditions\n\n  1. Female who is breastfeeding or pregnant\n  2. More than 15 VOCs within the 12 months prior to starting study treatment that required a hospital, emergency room (ER), or clinic visit\n  3. Hospitalized for sickle cell crisis or other vaso-occlusive event occurring in the 14 days prior to starting study treatment\n  4. Abnormal TCD in the 12 months prior to starting study treatment\n\n     Prior\u002FConcomitant Therapy\n  5. Patients receiving regularly scheduled blood (RBC) transfusion therapy (also termed chronic, prophylactic, or preventive transfusion)\n  6. Received any blood products within 30 days of starting study treatment\n  7. Receiving or use of concomitant medications that are strong inducers of cytochrome P450 (CYP) 3A4\u002F5 within 2 weeks of starting study treatment\n  8. Use of voxelotor within 28 days prior to starting study treatment or anticipated need for this agent during the study\n  9. Receipt of erythropoietin or other hematopoietic growth factor treatment within 28 days of starting study treatment or anticipated need for such agents during the study\n  10. Receipt of prior cellular based therapy (eg, hematopoietic cell transplant, gene modification therapy)",{"count":444,"type":22},95,[446],"PHASE2","This study is being done to learn about etavopivat, a once a day medicine taken by mouth in adolescents with sickle cell disease. The main goals are to study safety and how long etavopivat stays in the bloodstream, while also studying if there are benefits from taking etavopivat. Eligible participants who enter the study will start a 96-week treatment period. At the end of the 96 weeks, participants will have an end of study visit that occurs 4 weeks later. The participants will receive etavopivat every day throughout the treatment period.",[215],"2026-04-23",{"date":451,"type":33},"2026-04-24",{"date":453,"type":33},"2023-01-12",{"date":455,"type":22},"2029-08-08",{"name":457,"class":70},"Forma Therapeutics, Inc.",18,{"id":460,"slug":4,"hasResults":11,"nctId":461,"briefTitle":462,"officialTitle":462,"acronym":463,"eligibilityCriteria":464,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":465,"targetDuration":4,"studyType":145,"phases":4,"briefSummary":467,"conditions":468,"keywords":4,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":474,"leadSponsor":476,"locationsCount":478},"100634884","NCT07545486","Ablative Therapy of Oligometastatic Tumor After Response to Conventional First Line Treatment","ATOM-1st","Inclusion Criteria:\n\n1. Performance status 0 or 1 on the Eastern Cooperative Oncology Group (ECOG).\n2. Histologically diagnosis of one of these tumour types:\n\n   1. Hormone receptor positive, HER2 negative breast cancer\n   2. Triple negative breast cancer\n   3. HER2+ breast cancer\n   4. Non small cell lung cancer without oncogenic addiction\n   5. Head and Neck squamous cell carcinoma without recurrence in the radiation field\n   6. Gastric adenocarcinoma\n   7. Esophageal cancer (adenocarcinoma or epidermoid carcinoma)\n   8. Recurrent pancreatic cancer without local recurrence\n   9. Anal cancer\n   10. Bladder cancer\n   11. Clear cells renal cell carcinoma\n   12. Prostate cancer sensitive to castration\n   13. Adenocarcinoma endometrial cancer\n   14. Epidermoid carcinoma or adenocarcinoma of the cervix\n   15. Colorectal cancer\n   16. Recurrent Soft Tissue Sarcoma\n   17. Melanoma\n3. Patient with a decision by the local team to give OST and effective administration of OST. OST is defined as the most efficient choice in terms of survival in first line of advanced disease according to ESMO or other international guidelines. In case of multiple choice as first line, if no data provided direct evidence of superiority from one or the other options, there are all considered as OST. If the patient received a less efficient treatment because of his comorbidity or frailty, the eligible criteria won't be fulfilled.\n4. Have non-progressive disease after 3 to 6 months of treatment, and less than 6 weeks before presentation to the multidisciplinary team\n\n   1. Patients with complete response and no target lesion are excluded.\n   2. Patients with bone metastasis with remaining bone condensation or scare from tumoral activity may be eligible depending on metabolic activity of the lesion or local multidisciplinary committee decision concerning the risk of residual disease.\n5. After 3 to 6 months of treatment, and less than 6 weeks before start of LAT, patient must have an oligometastatic disease defined as all lesions (including primitive lesion) amenable to local ablative treatment according to local investigator team and respective local committee.\n\nExclusion Criteria:\n\n1. Patients who already received systemic antitumoral treatment in the advanced setting (including chemotherapy, immunotherapy, targeted therapy, …)\n2. Patients without OST administration\n3. Patients that have progressing lesion at any time point before decision of LAT by the expert committee\n4. Has a known recent history of other invasive tumour, excepted if local investigator may provide histologically data that all active lesions targeted are from the same cancer primitive.\n5. Radiotherapy or other LAT to any metastatic site before the start of OST.\n6. Exclusion criteria specific for France: Vulnerable persons according to the article L.1121-6 of the public health law (CSP), adults who are the subject of a measure of legal protection or unable to express their consent according to article L.1121-8 of the CSP",{"count":466,"type":22},1235,"Advancements in systemic antineoplastic therapies have led to improved overall survival rates for many solid tumors. However, metastatic disease remains a significant challenge and remains the leading cause of mortality for these patients. Additionally, there is a high attrition rate after first-line standard treatment across various tumor types, with studies indicating that 20-70% of patients may be unable to undergo second-line therapy, depending on the tumor type.\n\nThis highlights an urgent need to enhance outcomes from the first line of treatment. Although first-line therapy often represents the best available option, most patients experience relapse and disease progression despite an initial tumor response. This is attributed to both intrinsic and acquired resistance arising from the heterogeneity of primary tumors and metastases. To address this issue, metastasis-directed therapy (MDT) has been explored as a way to reduce tumor burden and mitigate the risk of resistance due to therapeutic selective pressure.\n\nMDT offers a promising opportunity to improve first-line treatment outcomes, but more precise patient selection criteria are needed to maximize therapeutic benefit and minimize the potential toxicity of ablative therapies. Indeed, despites its efficacy, fatal complication may occur so do grade 3 to 4 toxicities. Toxicity depends of the local ablative therapy (LAT) planned but as it will never be none, oncologists have to propose invasive treatment to patient that may benefit the most.\n\nBased on the published data, the investigators propose a pragmatic, selective approach centered on sensitivity to systemic therapy. The investigators aim to evaluate the benefit of local ablative therapy (LAT) in patients who demonstrate non-progressive disease after three months of first-line standard of care. Given the importance of this question across cancer subtypes, the investigators will employ a prospective database to enroll patients with various solid tumor type, excluding the ones for which the impact of LAT has already been explored or may be difficult to achieve. Outcomes of this strategy will be evaluated compared to outcomes from pivotal studies defining optimal standard first line therapy (OST) .\n\nSeveral analyses will be performed to better characterize the population for whom a multimodal approach may significantly improve their survival. The first one will aim to compare the median duration of response (mDOR) of the population treated with LAT compared to the mDOR reported by the pivotal study(ies) of each OST.\n\nThis study will serve as a proof of concept, supporting chemosensitivity as a viable selection factor for multimodal treatment in a broad range of cancer types.\n\nPrimary objective:\n\nImprovement of the duration of response (DOR) after completion of LAT compared to DOR reported in pivotal study that evaluated first line OST.\n\nSecondary objectives:\n\n* Evaluation of the safety of the addition of LAT.\n* Evaluation of overall progression free survival (PFS) and PFS at 1 year.\n* Evaluation of overall survival from OST start and from the time of LAT completion.\n* Documentation of acceptance and compliance to LAT decision by the institutional expert committee",[469],"Solid Tumor","2026-04-21",{"date":472,"type":33},"2026-04-22",{"date":350,"type":22},{"date":475,"type":22},"2036-06-01",{"name":477,"class":40},"Chirec",12,{"id":480,"slug":4,"hasResults":11,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":485,"targetDuration":4,"studyType":23,"phases":487,"briefSummary":488,"conditions":489,"keywords":500,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":41},"100635703","NCT07556133","Dexmedetomidine and Propofol for Sedation in Cataract Surgery.","Dexmedetomidine vs Propofol for Sedation in Cataract Surgery : a Prospective Randomized Controlled Trial.","Inclusion Criteria:\n\n* Adults undergoing cataract surgery\n\nExclusion Criteria:\n\n* Severe hepatic insufficiency\n* Third degree AV block\n* Patient refusal",{"count":486,"type":22},1000,[25],"The goal of this prospective, randomized, single-blinded is to learn if there is an ideal sedation protocol in cataract surgery in adults.\n\nThe main questions it aims to answer are:\n\n* Does the combination of Dexmedetomidine and Propofol affect significantly Ramsay sedation scale, compared to Dexmedetomidine and compared to Propofol?\n* How does each sedation protocol affect hemodynamics? (Heart rate and blood pressure)\n* Are respiratory events more common in a certain group?\n* Is the surgeon's satisfaction similar among groups?\n* Are adverse effects (bradycardia, hypotension, nausea) more common in a certain group?\n\nResearchers will compare 3 sedation protocols : Dexmedetomidine versus Propofol versus the combination of these 2 drugs and to see if one protocol is overall superior to the others. Fentanyl will also be used in all 3 sedation protocols.\n\nParticipants will :\n\n* Receive one of these three protocols\n* Be operated for one or both eyes\n* Monitored during the whole surgery and in the recovery room\n* Be evaluated by the Ramsay sedation scale by a trained Anesthesiologist or CRNA during surgery and in the recovery room Surgeons will be asked about how much they were satisfied.",[490,491,492,493,494,495,496,497,498,499],"Sedation","Cataract","Hemodynamic","Hemodynamic Changes","Dexmedetomidine","Propofol Dosage","Fentanyl","Bradycardia","Tachycardia","Nausea and Vomiting",[501,491,502,503,504],"Dexmedetomidine and propofol in cataract surgery","sedation","Dexmedetomidine in cataract surgery","Sedation for cataract surgery",{"date":506,"type":33},"2026-04-29",{"date":508,"type":33},"2025-11-09",{"date":510,"type":22},"2026-12-09",{"name":512,"class":40},"Saint-Joseph University",{"id":514,"slug":4,"hasResults":11,"nctId":515,"briefTitle":516,"officialTitle":517,"acronym":4,"eligibilityCriteria":518,"healthyVolunteers":11,"sex":519,"minAge":19,"maxAge":4,"enrollmentInfo":520,"targetDuration":522,"studyType":145,"phases":4,"briefSummary":523,"conditions":524,"keywords":527,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":529,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":534,"locationsCount":536},"100480992","NCT05543200","BPH Global Registry","A Global Registry of Treatments and Outcomes for Benign Prostatic Hyperplasia","Inclusion Criteria:\n\n* Primary diagnosis of BPH with LUTS with prescribed medical treatment or surgical intervention\n\nExclusion Criteria:\n\n* Non-symptomatic BPH\n* No treatment prescribed for BPH","MALE",{"count":521,"type":22},7500,"3 Years","Benign prostatic hyperplasia (BPH) is one of the most common performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been standardized. While data are available for the initial pivotal studies, post-market release data are lacking. Under the umbrella of uCARE, we have started a prospective, ongoing international registry for recording demographics and outcomes for patients undergoing surgical treatments for BPH.",[525,526],"Benign Prostatic Hyperplasia","Lower Urinary Tract Symptoms",[528],"BPH, Registry, LUTS",{"date":451,"type":33},{"date":531,"type":33},"2023-03-13",{"date":533,"type":22},"2027-03",{"name":535,"class":40},"Société Internationale d'Urologie",26,{"id":538,"slug":4,"hasResults":11,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":4,"eligibilityCriteria":542,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":543,"targetDuration":545,"studyType":145,"phases":4,"briefSummary":546,"conditions":547,"keywords":552,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":559,"locationsCount":560},"100084590","NCT00358943","International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry","Gaucher Disease Registry Protocol","Inclusion Criteria:\n\nICGG Gaucher Registry\n\n* All patients with a confirmed diagnosis of Gaucher disease are eligible for inclusion in the Registry. Confirmed diagnosis is defined as a documented β-glucocerebrosidase deficiency and\u002For mutation in the β-glucocerebrosidase gene.\n* For all patients, appropriate patient authorization will be obtained.\n\nGaucher Pregnancy Sub-registry:\n\n* be enrolled in the ICGG Gaucher Registry.\n* be pregnant, or have been pregnant with appropriate medical documentation available.\n* provide a signed informed consent and authorization form(s) to participate in the Sub-Registry prior to any Sub-Registry-related data collection being performed.\n\nExclusion Criteria:\n\n\\- No exclusion criteria for participation in the ICGG Gaucher Registry and Sub-registry.",{"count":544,"type":22},12000,"12 Months","The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.\n\nThe objectives of the Registry are:\n\n* To enhance understanding of the variability, progression, identification, and natural history of Gaucher disease, with the ultimate goal of better guiding and assessing therapeutic intervention.\n* To assist the Gaucher medical community with the development of recommendations for monitoring patients, and to provide reports on patient outcomes, to optimize patient care.\n* To characterize the Gaucher disease population.\n* To evaluate the long-term effectiveness of imiglucerase and of eliglustat.\n\nGaucher Pregnancy Sub-registry: The primary objective of this Sub-registry is to track pregnancy outcomes, including complications and infant growth, in all women with Gaucher disease during pregnancy, regardless of whether they receive disease-specific therapy. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician.If a patient consents to this Sub-registry, information about the patient's medical and obstetric history, pregnancy, and birth will be collected, and, if a patient consents to data collection for her infant, data on infant growth through month 36 postpartum will be collected.",[548,549,550,551],"Gaucher Disease","Cerebroside Lipidosis Syndrome","Glucocerebrosidase Deficiency Disease","Glucosylceramide Beta-Glucosidase Deficiency Disease",[548,550],"2026-04-13",{"date":555,"type":33},"2026-04-14",{"date":557,"type":33},"1991-04-01",{"date":161,"type":22},{"name":163,"class":70},318,{"id":562,"slug":4,"hasResults":11,"nctId":563,"briefTitle":564,"officialTitle":564,"acronym":4,"eligibilityCriteria":565,"healthyVolunteers":339,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":566,"targetDuration":4,"studyType":145,"phases":4,"briefSummary":567,"conditions":568,"keywords":577,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":41},"100633411","NCT07526337","Digital Planning and Clinical Assessment of the Treated Atrophic Posterior Maxilla With a Sinus Lift Procedure: a Cross-sectional Study.","Inclusion Criteria:\n\n* \\- Patient aged more than 18 years.\n* Partially edentulous patients having an implant rehabilitation treated with a sinus lift procedure in the atrophic posterior maxilla.\n* Patient with no systemic disease that contraindicate the surgical procedure as uncontrolled diabetes mellitus, bleeding disorders, recent myocardial infarction, head and neck radiation, and mental disorders.\n\nExclusion Criteria:\n\n* \\- Fully Edentulous patients.\n* Patients presenting sinus pathologies (sinusitis, thickening of the membrane).\n* Patient smoking more than 20 cigarettes.\n* Patient taking systemic drugs that could affect bone healing as immune suppressive drugs and bisphosphonates.\n* Patient with systemic disease that contraindicate the surgical procedure as uncontrolled diabetes mellitus, bleeding disorders, recent myocardial infarction, head and neck radiation, and mental disorders.",{"count":174,"type":22},"Maxillary posterior area is the most challenging site for dental implant placement. Indeed, complex remodeling processes, resulting in changes of the maxillary sinus and shape of the alveolar ridge will cause difficulties in rehabilitating the posterior maxillae sites. Various techniques have been proposed in order to achieve the necessary bone volume for the placement of long term successful implants. However, unbalanced crown to implant ratio remains a risk factor after successful dental implants installation following sinus graft. No study on humans assessed the effect of apical positioning of the implants in posterior grafted sites (sinus graft or sinus graft + vertical GBR) on the following clinical parameters: The peri-implant bone remodeling (vertical bone loss (mm) and probing depth (mm) around the implants, crown bulkiness, emergence profile and crown height, and Patients satisfaction, food impaction (PROM)).\n\nThis study will elucidate these points and based on the parameter's results, suggest a treatment based classification facilitating the treatment decision-making of the clinicians in case of an atrophic posterior maxilla; aiming to ensure a long-term successful supra-implant rehabilitation which will maintain its bio-mechanically and biological success.",[569,570,571,572,573,574,575,576],"Alveolar Bone Atrophy","Alveolar Bone Grafting","Peri-Implant Health","Sinus Floor Augmentation","Vertical Ridge Deficiency","Guided Bone Regeneration","Digital Guided Bone Regeneration","Prosthetic Complication",[578,579,580,581,582,583,584,585],"alveolar bone atrophy","digital planning","guided bone regeneration","maxillary sinus","peri-implant disease","peri-implantits","sinus floor augmentation","vertical ridge deficiency","2026-04-06",{"date":553,"type":33},{"date":589,"type":33},"2025-01-01",{"date":591,"type":22},"2026-05-30",{"name":512,"class":40},{"id":594,"slug":4,"hasResults":11,"nctId":595,"briefTitle":596,"officialTitle":597,"acronym":4,"eligibilityCriteria":598,"healthyVolunteers":339,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":599,"targetDuration":545,"studyType":145,"phases":4,"briefSummary":600,"conditions":601,"keywords":605,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":610,"startDateStruct":611,"completionDateStruct":612,"leadSponsor":613,"locationsCount":41},"100633395","NCT07526129","Impact of Alveolar Ridge Preservation on the Potential Need for Sinus Floor Elevation: A 10-year Retrospective Radiographical Study","Impact of Alveolar Ridge Preservation on the Potential Need for Sinus Floor Elevation in Posterior Maxillary Implant Sites: A 10-year Retrospective Radiographical Study","Inclusion Criteria:\n\n* • Patients aged ≥18 years.\n\n  * Patients who underwent alveolar ridge preservation after extraction of maxillary posterior teeth, as a test group.\n  * Patients who underwent extraction of maxillary posterior teeth with unassisted socket healing without alveolar ridge preservation as a control group.\n\nExclusion Criteria:\n\n* • The presence of a clinically symptomatic periapical radiolucency, acute abscesses, or chronic sinus tract, that may falsify the classification of posterior maxillary teeth on 2D radiographs.",{"count":311,"type":22},"This research aims to investigate the influence of alveolar ridge preservation, after extraction of maxillary posterior teeth, on the potential need of sinus floor augmentation procedures (that include lateral or crestal sinus augmentations). From peri-apical radiographs, maxillary posterior teeth will be divided into 4 groups according to the relationship of their apexes with the sinus. Then, the patients will be divided into 2 sub-groups: unassisted socket healing (only extraction) and ARP group (extraction + ARP) and their CBCT scans before implant placement will be collected. The CBCT scans should be at least 4 months post-extraction and ARP. Depending on the residual bone height, patients will be divided into 3 categories, according to the ABC classification:\n\n1. In need of lateral sinus floor augmentation\n2. In need of crestal sinus floor augmentation\n3. No need for sinus floor augmentation, therefore, implant placement.\n\nThese divisions will be conducted, according to:\n\n\\- The residual bone height (RBH) which is the height in mm from the alveolar ridge crest to the lowest point of the maxillary sinus floor.\n\nThe results of the proposed hypothesis are verified and interpreted after statistical analysis.",[602,572,603,569,604],"Alveolar Bone Loss","Sinus Pneumatization","Alveolar Ridge Preservation",[606,607,608,609,584],"alveolar bone loss","alveolar process atrophy","extraction","tooth socket",{"date":553,"type":33},{"date":589,"type":33},{"date":591,"type":22},{"name":512,"class":40},{"id":615,"slug":4,"hasResults":11,"nctId":616,"briefTitle":617,"officialTitle":618,"acronym":4,"eligibilityCriteria":619,"healthyVolunteers":339,"sex":17,"minAge":144,"maxAge":274,"enrollmentInfo":620,"targetDuration":4,"studyType":23,"phases":622,"briefSummary":623,"conditions":624,"keywords":629,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":636,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":642,"locationsCount":41},"100627534","NCT07449884","AI Avatar Video vs. Tell-Show-Do for Reducing Anxiety and Improving Cooperation in Children During Local Anesthesia","Artificial Intelligence-driven Avatar-based Video vs. Tell-show-do for Reducing Anxiety and Improving Cooperation in Children During Local Anesthesia: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Inclusion Criteria:\n\n  * Children aged 5 to 7 years\n  * Medically healthy (ASA I)\n  * Cooperative behavior during dental examination\n  * No known allergy to local anesthetics\n  * Require non-urgent dental treatment under local anesthesia\n  * First-time experience receiving local anesthesia\n  * Able to understand and communicate\n\nExclusion Criteria:\n\n* History of epilepsy\n* Diagnosed anxiety or behavioral disorders\n* Cognitive or developmental delay\n* Hearing or visual impairment\n* Previous experience with dental anesthesia\n* Require inferior alveolar nerve block anesthesia\n\nExclusion Criteria:\n\n\\-",{"count":621,"type":22},70,[25],"This randomized clinical trial aims to compare two behavior guidance techniques used to reduce anxiety in children during local anesthesia injections in dental treatment. The study evaluates the traditional Tell-Show-Do (TSD) technique versus an artificial intelligence (AI)-driven, avatar-based video method called the \"Mini Dentist.\"\n\nChildren aged 5 to 7 years who require local anesthesia for routine dental treatment will be randomly assigned to one of two groups. The control group will receive the conventional Tell-Show-Do explanation from the pediatric dentist. The experimental group will watch a short animated video featuring an AI-generated avatar that explains and demonstrates the procedure in a child-friendly manner before the injection.\n\nAnxiety and behavior will be assessed using heart rate monitoring, behavioral observation (FLACC scale), and a self-reported pain scale (Wong-Baker FACES). The goal is to determine whether the AI-based method improves cooperation and reduces anxiety compared to the traditional approach.\n\nParticipation is voluntary, and all procedures follow ethical research standards.",[625,626,627,628],"Anxiety","Fear","Local Anesthesia","Pediatric Dentistry",[630,631,632,633,634],"Artificial intelligence","Child behavior","Dental anxiety","Local anesthesia.","Randomized Controlled trial","2026-03-24",{"date":637,"type":33},"2026-03-30",{"date":639,"type":33},"2026-02-16",{"date":641,"type":22},"2027-05-30",{"name":512,"class":40},{"id":644,"slug":4,"hasResults":11,"nctId":645,"briefTitle":646,"officialTitle":646,"acronym":4,"eligibilityCriteria":647,"healthyVolunteers":339,"sex":648,"minAge":649,"maxAge":650,"enrollmentInfo":651,"targetDuration":4,"studyType":23,"phases":653,"briefSummary":654,"conditions":655,"keywords":659,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":661,"lastUpdatePostDateStruct":662,"startDateStruct":664,"completionDateStruct":666,"leadSponsor":667,"locationsCount":41},"100629964","NCT07481513","Impact of Intermittent Fasting on the Mental Health of Perimenopausal Women","Inclusion Criteria:\n\n* Participants eligible in this study will be women between the ages of 45 and 55 who are in the perimenopausal stage as defined by the STRAW criteria and confirmed using the Menopausal Rating Scale (MRS).\n\nExclusion Criteria:\n\n* Currently using hormone replacement therapy\n* Diagnosed with severe medical conditions that could interfere with fasting, including uncontrolled diabetes, heart disease, hypertension, cancer or kidney disease\n* Have a current formal mental health diagnosis as defined by the DSM-5, regardless of whether they are receiving medication or therapy\n* Experiencing any form of dementia\n* Have undergone surgical menopause, have premature ovarian failure, are currently undergoing chemotherapy or radiotherapy, or are ovarian cancer survivors\n* Are currently pregnant. undergoing treatment for endometriosis, have significant thyroid disorders, or are on any form of hormone therapy\n* Do not speak English\n* Participants who score greater than 0 on question 9 of the PHQ-9 (including suicidal ideation) will be removed from the trial and provided with mental health referrals to NGOs for support.","FEMALE","45 Years","55 Years",{"count":652,"type":22},140,[25],"This study will explore how intermittent fasting (specifically the 16\u002F8 method) affects the mental health of women who are in the perimenopause stage. This life stage often brings hormonal changes that can impact emotional and physical well-being. The study will include 98 women aged 45-55, who will be randomly divided into two groups. The study will compare the mental health outcomes of those who follow intermittent fasting with those who do not, using independent t-tests to analyze the results. The goal is to better understand if intermittent fasting can help improve mental health during perimenopause.",[656,657,658],"Mental Health","Perimenopause","Intermittent Fasting",[658,656,657,660],"Depression","2026-03-16",{"date":663,"type":33},"2026-03-19",{"date":665,"type":33},"2025-09-23",{"date":379,"type":22},{"name":39,"class":40},{"id":669,"slug":4,"hasResults":11,"nctId":670,"briefTitle":671,"officialTitle":672,"acronym":4,"eligibilityCriteria":673,"healthyVolunteers":11,"sex":17,"minAge":674,"maxAge":4,"enrollmentInfo":675,"targetDuration":4,"studyType":23,"phases":677,"briefSummary":678,"conditions":679,"keywords":681,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":690,"lastUpdatePostDateStruct":691,"startDateStruct":693,"completionDateStruct":695,"leadSponsor":697,"locationsCount":41},"100629407","NCT07474272","Non-Surgical Treatment of Periodontitis With Adjunctive Sodium Hypochlorite\u002FAmino Acids and Cross-Linked Hyaluronic Acid","Non-Surgical Treatment of Periodontitis With Adjunctive Sodium Hypochlorite \u002FAmino Acids and Cross-Linked Hyaluronic Acid: Randomized Controlled Trial","Inclusion Criteria:\n\n* Localized periodontal pocket with a probing depth ≥ 6 mm and a clinical - attachment loss of \\> 3 mm (periodontitis stage III or IV; classification of the European Federation of Periodontology and American Academy of Periodontology);\n* Patients who signed the written informed consent and is willing to cooperate;\n* Bleeding on probing in more than 30% of the sites.\n\nExclusion Criteria:\n\n* Medical history likely to affect periodontal status and\u002For to compromise treatment outcomes;\n* Patients who received antibiotic and\u002For anti-inflammatory treatments the last 6 months\n* Patients who received immunosuppressors treatments the last 6 months;\n* Patients who received any periodontal therapy for the last 6 months;\n* Pregnant or lactating women;\n* Smokers smoking more than 10 cigarettes per day.","16 Years",{"count":676,"type":22},78,[25],"The goal of this clinical trial is to learn if using sodium hypochlorite\u002Famino acid gel, with or without cross-linked hyaluronic acid, as an addition to standard non-surgical periodontal therapy works to treat periodontitis in adults. It will also learn about the safety of these treatments. The main questions it aims to answer are:\n\nDoes the adjunctive treatment reduce bleeding on probing, plaque index, and periodontal pocket depth?\n\nWhat medical or dental problems do participants have when receiving these treatments?\n\nResearchers will compare:\n\nStandard non-surgical periodontal therapy alone\n\nStandard therapy plus sodium hypochlorite\u002Famino acid gel\n\nStandard therapy plus sodium hypochlorite\u002Famino acid gel and cross-linked hyaluronic acid (\"Clean and Seal\" protocol)\n\nParticipants will:\n\nReceive their assigned treatment during one clinical session per the study protocol\n\nHave clinical measurements taken before treatment and at three months after treatment\n\nBe monitored for any dental or medical adverse events related to the procedures",[680],"Periodontitis",[682,683,684,685,686,687,688,689],"periodontal pocket","periodontitis","periodontal disease","deep periodontal pocket","localized periodontitis","generalized periodontitis","non-surgical treatment of periodontitis","non-surgical periodontal treatment","2026-03-14",{"date":692,"type":33},"2026-03-17",{"date":694,"type":22},"2026-03-11",{"date":696,"type":22},"2026-08",{"name":698,"class":40},"Marwan El Mobadder",""]